Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate if tocilizumab's efficacy varies between hypoinflammatory and hyperinflammatory subphenotypes in COVID-19-related ARDS.
Conducted a retrospective analysis using data from three biobanks.
Included mechanically ventilated COVID-19 patients from ICUs of teaching hospitals.
Administered tocilizumab to some patients while others received no treatment.
Classified patients into inflammatory subphenotypes using a classifier model.
Tocilizumab significantly reduced 30-day mortality in the overall patient cohort (p = 0.014).
95% of patients were classified as hypoinflammatory and 5% as hyperinflammatory.
No significant difference in treatment effectiveness was observed between subphenotypes (p = 0.59).

We only have this paper's title and publication details.

Retrospective analysis examines tocilizumab's impact on mortality in COVID-19 patients, suggesting no difference by inflammatory subphenotype.

No takes yet. Share an insight, caveat, or question.

Filippini et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share